摘要
目的：观察清开灵注射液治疗重型肝炎的疗效。方法：将８３例重型肝炎患者随机分为２组，治疗组５０例在常规治疗基础上加用清开灵注射液治疗，对照组３３例采用常规治疗。结果：治疗组病死率为４２．０％，对照组为６３．６％，２组比较有显著性差异（Ｐ＜０．０５），２组血清胆红素降至正常时间〔（４５．２±３５．８）日和（７３．３±４８．９）日〕、腹水消退时间〔（４５．８±３９．２）日和（７６．１±４５．３）日〕及病程中出现肝性脑病（６例和１０例）和感染（２例和６例）等并发症例数的比较，亦有显著性差异（Ｐ均＜０．０５），治疗组疗效优于对照组。结论：清开灵注射液是治疗重型肝炎的有效药物，可降低血清胆红素、消退腹水、防治主要并发症，从而提高存活率。
Objective :To observe the curative effects of Qingkailing Injection (QKLI) on severe hepatitis. Methods :83 cases with severe hepatitis were randomly divided into two groups.The treatment group (n=50) was treated with QKLI based on conventional therapy,otherwise control group (n=33) treated with conventional therapy alone. Results :The mortality rate in treatment group (420%) was significantly lower than that (636%) in control group (P<005).The times for serum bilirubin to reduce to normal (452358)d vs.(733489)d and ascites to subside (458392)d vs.(761453)d,meanwhile the numbers complicating hepatic encephalopathy (6 cases vs.10 cases) and infections (2 cases vs.6 cases) during ill course in comparison between treatment group and control group were significantly different (all P<005).The curative effects in treatment group were superior to those in control group. Conclusions :QKLI is an effective drug in treating severe hepatitis and is able to reduce serum bilirubin,subside ascites,and prevent and
关键词
重型肝炎
慢性
清开灵注射液
中医药疗法
疗效
chronic severe hepatits
Qingkailing Injectiontreat main complications so that to increase survivor rate.
